Skip to main content
RPG Life Sciences Limited logo

RPG Life Sciences Limited — Investor Relations & Filings

Ticker · RPGLIFE ISIN · INE105J01010 LEI · 335800O9C9JKWKXY5Y66 BSE.NS Manufacturing
Open in API
Filings indexed 814 across all filing types
Latest filing 2023-10-18 Audit Report / Informat…
Country IN India
Listing BSE.NS RPGLIFE

About RPG Life Sciences Limited

https://www.rpglifesciences.com

RPG Life Sciences Limited is an integrated pharmaceutical enterprise engaged in the development, manufacturing, and marketing of a diverse range of generic and branded formulations, as well as Active Pharmaceutical Ingredients (APIs). The company operates across several therapeutic segments, including nephrology, oncology, cardiology, rheumatology, and gastroenterology. It maintains a significant presence in the immunosuppressant market, providing critical medications for transplant recipients. With a focus on research and development, the organization produces complex molecules and finished dosages that cater to both domestic and international healthcare markets. Its manufacturing facilities adhere to stringent global quality standards, enabling the supply of essential medicines to regulated and semi-regulated markets worldwide. The portfolio includes a mix of legacy brands and specialty products designed to address chronic and acute medical conditions.

Recent filings

Filing Released Lang Actions
Related Party Transactions
Audit Report / Information Classification · 95% confidence The document contains detailed disclosures of related party transactions, including remuneration, purchases, payments, and contributions involving key management personnel and entities under significant influence. The content is focused on financial and transactional details related to related parties, which is typical of disclosures found in audit reports or notes to financial statements. There is no indication that this is a full annual report, earnings release, or a presentation. The document is not an announcement or a certification but a substantive disclosure of related party transactions, which is commonly part of audit or regulatory compliance reporting. Therefore, the most appropriate classification is Audit Report / Information (AR).
2023-10-18 English
Press Release
Earnings Release Classification · 95% confidence The document is a press release announcing the financial results for the second quarter and half year ended September 30, 2023, for RPG Life Sciences Limited. It contains key financial highlights such as revenue growth, profit before tax (PBT), and EBITDA margins, but it is concise and does not include detailed financial statements or comprehensive analysis. The length is 3934 characters, which is relatively short and typical for an earnings release announcement. The document is not a full interim or quarterly report (IR) because it lacks substantive financial data and detailed financial statements. It is also not a full annual report (10-K) or management discussion and analysis (MDA). Therefore, the best classification is Earnings Release (ER), which fits initial announcements of quarterly or periodical financial results with key highlights only.
2023-10-18 English
Updates
Regulatory Filings
2023-10-18 English
Financial Result Updates
Regulatory Filings
2023-10-18 English
Outcome of Board Meeting
Regulatory Filings
2023-10-18 English
Loss of Share Certificates
Regulatory Filings
2023-10-16 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.